2019 JITC Best Paper Award Recipients

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

LSC HS
CSinclair HS

Larissa S. Carnevalli, phd

AstraZeneca

Charles Sinclair, phd

Bristol-Myers Squibb

“PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity”
Larissa S. Carnevalli†, Charles Sinclair†, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M.L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, and Simon T. Barry
†Contributed equally

Journal for ImmunoTherapy of Cancer 2018, 6:109 (22 October 2018)

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Amin headshot

Asim amin, md, phd

Levine Cancer Institute

“Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study”
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y.C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers

Journal for ImmunoTherapy of Cancer 2018, 6:109 (22 October 2018)

Return to ...